In the context of cancer, the inflammasome-IL-1 axis can be perceived as a double-edged sword with both pro- and antitumorigenic properties, which is extensively summarized in a recent paper by Rébé and Ghiringhelli (273). The gene discussed is IL1A; the disease is cancer.